Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.

Gut - 1 Feb 2015

Liu Chen-Hua, Liu Chun-Jen, Huang Chung-Feng, Lin Jou-Wei, Dai Chia-Yen, Liang Cheng-Chao, Huang Jee-Fu, Hung Peir-Haur, Tsai Hung-Bin, Tsai Meng-Kun, Lee Chih-Yuan, Chen Shih-I, Yang Sheng-Shun, Su Tung-Hung, Yang Hung-Chih, Chen Pei-Jer, Chen Ding-Shinn, Chuang Wan-Long, Yu Ming-Lung, Kao Jia-Horng

Abstract excerpt

OBJECTIVE: Data comparing the efficacy and safety of combination therapy with peginterferon plus low-dose ribavirin and peginterferon monotherapy in treatment-naive haemodialysis patients with hepatitis C virus genotype 2 (HCV-2) infection are limited. DESIGN: In this randomised trial, 172 patients received 24 weeks of peginterferon alfa-2a 135 μg/week plus ribavirin 200 mg/day (n=86) or peginterferon alfa-2a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythropoietin

Share to Hemoglobins

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Renal Dialysis

Share to Ribavirin

Source

Identifiers

PMID: 24747867
DOI: 10.1136/gutjnl-2014-307080

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.PMID 24747867Read ↗

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.Semantic proximity Read ↗

Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.Semantic proximity Read ↗

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.Semantic proximity Read ↗

Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

Safety and efficacy of an escalating dose regimen of pegylated interferon alpha-2b in the treatment of haemodialysis patients with chronic hepatitis C.Semantic proximity Read ↗

Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.Semantic proximity Read ↗

Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.Semantic proximity Read ↗

Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.Semantic proximity Read ↗

Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.Semantic proximity Read ↗

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.Semantic proximity Read ↗

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.